Publications
Partners
Johannesburg - President Jacob Zuma is scheduled to open a new R329m state-of-the-art pharmaceutical manufacturing facility in Durban, KwaZulu Natal, owned by JSE-listed Cipla Medpro South Africa [JSE:CMP], on Wednesday.
Cipla Medpro Manufacturing (CMM) houses the company's Durban-based MCC-approved manufacturing facility - one of the largest pharmaceutical manufacturing plants of its kind in South Africa.
CMSA Limited, which recently invested R329m in upgrading the plant to international Pharmaceutical Inspection Co-operation Scheme (PIC/s) standards, offers high volume contract manufacturing solutions in line with cGMP and PIC/s standards to both large local and multinational pharmaceutical companies, including select lines of the group's own products.
The facility is also one of only two plants in South Africa offering manufacturing capability for effervescent formulations.
In recognition of the important role played by education in the development of the country, Cipla Medpro will, simultaneously with the commissioning of its new manufacturing plant, make a R1.5m donation to the Jacob Zuma RDP Educational Trust.
In accordance with the wishes of Cipla Medpro, the educational grant will be used primarily in the field of post-matric studies in engineering, medicine and pharmaceutical studies.
Says S'bu Luthuli, Chairperson of Cipla Medpro: "We are making this donation to the Jacob Zuma RDP Educational Trust in acknowledgement of the important role that tertiary technical education in the fields of science, medicine and engineering plays in the development of our country.
"A core principal of Cipla Medpro is a belief that affordable healthcare is a right for all South Africans, not a privilege. To this end, we are firmly committed to providing world class, yet affordable medicines to all."
CMSA has a long-standing relationship with Cipla India, the largest stand alone generic company in the world and number one pharmaceutical company in India by value, which enables it access to Cipla India's impressive pipeline of products.
The company is busy finalising a new transaction in terms of which Cipla India will eventually acquire a 25% stake in Cipla Medpro Manufacturing.
Once the transaction has been concluded, Cipla India will be in the position to place additional volumes with CMM's manufacturing facility as well as assist the company in achieving the much sought after United Nations public health arm WHO (World Health Organisation) status and FDA (Food and Drug Administration) manufacturing approvals.
Says Jerome Smith, CEO of Cipla Medpro: "Thanks to our strong alliances we are poised to be a significantly greater provider of low cost, effective, quality medicines in the growing generics market, aiding in the effective and ongoing treatment of human ailments.
"Our Durban facility is presently contract manufacturing eight State tender products for Cipla Medpro, based in Cape Town, including two Antiretrovirals, Efavirenz and Lamivudine. And the factory will also manufacture the ARVs, Nevirapine and Tenofovir.
"We believe that a positive outcome on Government's ARV tender will allow us to take advantage of the abundant capacity of our plant, as well as empowering Cipla Medpro with the potential opportunity for job creation and the expansion of our 341-strong diverse work force based at the factory."
Cipla Medpro Manufacturing (CMM) houses the company's Durban-based MCC-approved manufacturing facility - one of the largest pharmaceutical manufacturing plants of its kind in South Africa.
CMSA Limited, which recently invested R329m in upgrading the plant to international Pharmaceutical Inspection Co-operation Scheme (PIC/s) standards, offers high volume contract manufacturing solutions in line with cGMP and PIC/s standards to both large local and multinational pharmaceutical companies, including select lines of the group's own products.
The facility is also one of only two plants in South Africa offering manufacturing capability for effervescent formulations.
In recognition of the important role played by education in the development of the country, Cipla Medpro will, simultaneously with the commissioning of its new manufacturing plant, make a R1.5m donation to the Jacob Zuma RDP Educational Trust.
In accordance with the wishes of Cipla Medpro, the educational grant will be used primarily in the field of post-matric studies in engineering, medicine and pharmaceutical studies.
Says S'bu Luthuli, Chairperson of Cipla Medpro: "We are making this donation to the Jacob Zuma RDP Educational Trust in acknowledgement of the important role that tertiary technical education in the fields of science, medicine and engineering plays in the development of our country.
"A core principal of Cipla Medpro is a belief that affordable healthcare is a right for all South Africans, not a privilege. To this end, we are firmly committed to providing world class, yet affordable medicines to all."
CMSA has a long-standing relationship with Cipla India, the largest stand alone generic company in the world and number one pharmaceutical company in India by value, which enables it access to Cipla India's impressive pipeline of products.
The company is busy finalising a new transaction in terms of which Cipla India will eventually acquire a 25% stake in Cipla Medpro Manufacturing.
Once the transaction has been concluded, Cipla India will be in the position to place additional volumes with CMM's manufacturing facility as well as assist the company in achieving the much sought after United Nations public health arm WHO (World Health Organisation) status and FDA (Food and Drug Administration) manufacturing approvals.
Says Jerome Smith, CEO of Cipla Medpro: "Thanks to our strong alliances we are poised to be a significantly greater provider of low cost, effective, quality medicines in the growing generics market, aiding in the effective and ongoing treatment of human ailments.
"Our Durban facility is presently contract manufacturing eight State tender products for Cipla Medpro, based in Cape Town, including two Antiretrovirals, Efavirenz and Lamivudine. And the factory will also manufacture the ARVs, Nevirapine and Tenofovir.
"We believe that a positive outcome on Government's ARV tender will allow us to take advantage of the abundant capacity of our plant, as well as empowering Cipla Medpro with the potential opportunity for job creation and the expansion of our 341-strong diverse work force based at the factory."
